Core Insights - Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small molecule precision medicines for central nervous system (CNS) disorders [2] Group 1: Company Overview - The company is dedicated to discovering and developing transformational precision neuromedicines for patients with CNS disorders [2] - Rapport's founders have made pioneering discoveries related to receptor associated proteins (RAPs) in the brain, forming the basis of the company's RAP technology platform [2] - The precision neuroscience pipeline includes the lead clinical program, RAP-219, which targets a RAP expressed in specific brain regions [2] Group 2: Clinical Programs - RAP-219 is currently in clinical trials for focal epilepsy, peripheral neuropathic pain, and bipolar disorder [2] - Additional preclinical and late-stage discovery programs are targeting CNS disorders such as chronic pain and hearing disorders [2] Group 3: Upcoming Events - Management will participate in fireside chats at the Stifel Healthcare Conference on November 18, 2024, and the Jefferies London Healthcare Conference on November 20, 2024 [1]
Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November